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Myopathy is a feature of many inflammatory syndromes. Chronic inflammation has
been linked to pathophysiological mechanisms which implicate 1,25 dihydroxyvitamin D3
(1,25-(OH)2D3)-mediated signaling pathways with emerging evidence supporting a role
for the vitamin D receptor (VDR) in contractile and metabolic function of both skeletal
and cardiac muscle. Altered VDR expression in skeletal and cardiac muscle has been
reported to result in significant effects on metabolism, calcium signaling and fibrosis in
these tissues. Elevated levels of serum inflammatory cytokines, such as IL-6, TNF-α and
IFNγ, have been shown to impact myogenic and nuclear receptor signaling pathways
in cancer-induced cachexia. The dysregulation of nuclear receptors, such as VDR and
RXRα in muscle cells, has also been postulated to result in myopathy via their effects on
muscle structural integrity and metabolism. Future research directions include generating
transcriptome-wide information incorporating VDR and its gene targets and using systems
biology approaches to identify altered molecular networks in human tissues such as
muscle. These approaches will aid in the development of novel therapeutic targeting
strategies for inflammation-induced myopathies.
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VITAMIN D AND MUSCLE FUNCTION
Vitamin D is necessary for the maintenance of structural integrity
and function of the musculoskeletal system (Pfeifer et al., 2002).
Severe deficiency results in impaired bone strength and deforma-
tion i.e., rickets in children and osteomalacia in adults. Vitamin
D plays a significant role in calcium homeostasis and bone
metabolism through its actions on target tissues (DeLuca, 2004).
Serum vitamin D levels have been correlated to muscle cell con-
tractility, muscle strength, and postural stability (Rodman and
Baker, 1978; Marcinkowska, 2001; Grimaldi et al., 2013; Girgis
et al., 2014). Low serum levels have been related to proximal mus-
cle weakness, gait disturbance, paresthesia, and discomfort within
the muscles (Skaria et al., 1975; Schott and Wills, 1976; Glerup
and Eriksen, 1999; Glerup et al., 2000; Pfeifer et al., 2002; Ahmed
et al., 2009).
The clinical features of myopathy associated with severe vita-
min D deficiency are supported by findings of abnormal histo-
logical and electrophysiological changes in muscle. Histological
analysis of skeletal muscle biopsied from adults with vitamin
D deficiency reveal enlarged inter-fibrillar spaces, infiltration of
fat, presence of glycogen granules, fibrosis, and type II mus-
cle fiber (fast-twitch) atrophy (Sorensen et al., 1979; Yoshikawa
et al., 1979; Boland, 1986; Sato et al., 2005). Recent inter-
est has been in reversal of some of these pathological effects
of this clinical syndrome. Meta-analysis of randomized con-
trolled trials in the elderly with low serum levels of vitamin
D, demonstrated a decrease in the risk of falls following sup-
plementation with vitamin D (Rejnmark, 2011). This outcome
has been attributed to the ability of vitamin D to impact mus-
cle fiber composition hence skeletal muscle structure. Studies
in vitamin D deficient patients revealed an increase in percent-
age of type II fibers, a significant increase in mean type II
muscle fiber diameter and area particularly of type IIa mus-
cle fibers following treatment with 1-α-hydroxyvitaminD3 and
calcium. However, it is still unclear if vitamin D supplemen-
tation induced formation of new type II fibers or increased
transition of existing type I fibers from to type II (Sorensen
et al., 1979; Sato et al., 2005). Vitamin D has also been demon-
strated to increase cell proliferation and inhibit apoptosis in
injured rat soleus skeletal muscle, with positive functional out-
comes such as faster recovery of contraction forces (Stratos et al.,
2013). The therapeutic potential of vitamin D supplementa-
tion has also recently been tested on dysferlin gene regulation
and dysferlinopathies (autosomal recessive neuromuscular disor-
der characterized by progressive muscle wasting due to dysferlin
gene mutations and a deficiency of functional dysferlin protein).
Vitamin D increased dysferlin gene expression in both HL60
monocytes and skeletal muscle cells via the activation of vita-
min D receptor (VDR) which binds to the dysferlin promoter;
and non-genomic MEK/ERK signaling and classical genomic
effects. 1,25(OH)2D3 has also been reported to suppress myotube
formation by decreasing Myf5 and myogenin gene expression
resulting in increased myotube diameters but reduced myo-
statin expression potentially alleviating the myopathic effects of
muscle weakness and reduced contractile function (Luna et al.,
2012).
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Experiments in C2C12 cells highlight some key molecular reg-
ulatory effects of 1,25(OH)2D3 including: (1) increased expres-
sion and nuclear translocation of the VDR, (2) decreased cell
proliferation, (3) decreased IGF-I expression, and (4) increased
IGF-II and follistatin expression and decreasing the expression of
myostatin which appeared to promote myogenic differentiation
and (5) altered differentiation and myotube size. Hence, vitamin
D may also be considered for use in intervention studies for mus-
cle conditions that involve these mechanisms (Garcia et al., 2011;
Girgis et al., 2014).
THE ROLE OF VITAMIN D RECEPTOR IN MUSCLE FUNCTION
The effects of vitamin D are modulated by its receptor, there-
fore the expression and distribution of VDR is of significant
importance. Early studies demonstrated the presence of the VDR
in cultured human myoblasts and myotubes which showed a
response to physiological concentrations of 1,25-(OH)2D3. VDR
is also present in human skeletal muscle cells within the nuclei
and has been shown to play a role in skeletal muscle development,
my fiber size and morphology (Simpson et al., 1985; Costa et al.,
1986; Bischoff et al., 2001; Bischoff-Ferrari et al., 2006). Skeletal
muscle development requires a co-ordinated series of transcrip-
tion factor and growth factor events that enable progenitor cells
to undergomyoblast determination (requiring Pax3, Pax7,MyoD,
and Myf5) then myoblast to myotube determination (requir-
ing p21Cip1, myogenin, MEF2C and Rb) then further myotube
maturation requiring innervation, MRF4, MLP) (Ludolph and
Konieczny, 1995; Perry and Rudnicki, 2000; Ryhänen et al.,
2003; Miyazawa et al., 2005; Washington et al., 2011). VDR and
myosin heavy chain isoform was shown to co-localize in skele-
tal muscle biopsies in older female subjects (Ceglia et al., 2010).
VDR has also been shown to impact the expression of myo-
genic transcriptional regulators, in particular Myf5, myogenin,
E2A, and early myosin heavy chain isoforms (Endo et al., 2003;
Girgis et al., 2014). C2C12 myoblasts treated with 1,25-(OH)2D3
showed increased VDR and CYP24A1 expression above endoge-
nous levels which resulted in inhibition in cell proliferation
(Srikuea et al., 2012; Girgis et al., 2014). Furthermore, inhibition
of myogenic differentiation of C2C12 and G8 cell lines was also
achieved with suppression of VDR expression, suggesting that
myoblasts require signals transmitted through VDR for differ-
entiation into myocytes. Myogenic differentiation likely involves
the orchestration of myogenic transcription factors in skeletal
muscle (Girgis et al., 2013). Vitamin D signaling may modu-
late p21CIP1 and Rb as well as myogenin, which are important
in myogenic differentiation of myoblasts to myotubes (Ludolph
and Konieczny, 1995; Perry and Rudnicki, 2000). Autocrine vita-
min D signaling has also been reported to regulate functional
effects such as contraction and remodeling in smooth muscle
cells although the autocrine effects in skeletal and cardiac mus-
cles still require characterization (Weisman et al., 2005; Maghni
et al., 2007; Eggersdorfer and Stöcklin, 2013).
Effects in VDR-null mutant mice further highlight the impor-
tance of the VDR in muscle biology. Apart from the observed
growth retardation, osteomalacia and systemic metabolic changes
such as secondary hyperparathyroidism and hypocalcemia, these
mutant mice also had abnormal muscle structure and function
(Burne et al., 2005). VDR-null mutant mice displayed a pro-
gressive decrease in their muscle fiber diameters compared to
those of wild-type mice, which was evident early in the postna-
tal period (prior to weaning) and associated with an abnormally
high expression of myogenic differentiation factors. These obser-
vations suggest alterations in muscle cell differentiation pathways
and thus abnormal muscle fiber development and maturation
(Endo et al., 2003). Interestingly, the muscle fiber abnormalities
described were diffuse without any preference for type I or II
fibers, which was different to myopathy due to vitamin D defi-
ciency where there was a predominance of type II fiber loss.
Additionally, themutantmice had a total 33% body weight reduc-
tion compared to controls at maturity; implying a post-natal role
for VDR inmaintaining weight (Song et al., 2003). Increased VDR
expression is also correlated with regeneration (Srikuea et al.,
2012), but levels of VDR appear to decrease with increasing age,
which has been proposed as a potential mechanism contributing
to reduced muscle strength in the Bischoff-Ferrari et al. (2004).
In the context of muscle biology, VDR mediates both non-
genomic and genomic effects of vitamin D (Buitrago et al., 2001;
Capiati et al., 2002). VDR knock-down experiments demon-
strated that 1,25-(OH)2D3-induced p38 MAPK activity occurs
through Src phosphorylation, while also reducing ERK1/2 and
Akt activity. These non-genomic effects include the stimulation
of transmembrane second messenger systems involving adenylyl
cyclase/cAMP/PKA and PLC/DAG+IP3/PKC to affect contrac-
tile function and myogenesis. Furthermore, 1,25−(OH)2D3has
also been reported to mediate Ca2+release through voltage and
store dependent calcium channels (SOC, CEE) in avian muscle
cells (Santillan et al., 2004). Caveolae have also been shown to
be involved in 1,25−(OH)2D3activation of in c-Src-MAPKs in
C2C12 cells. Ca2+ influx in caveolae is triggered by the interac-
tion between VDRwith TRCP3, an integral protein of capacitative
Ca2+ entry (CCE) (Buitrago and Boland, 2010; Buitrago et al.,
2011).
New perspectives on vitamin D, chronic inflammation, and muscle
physiology
Valuable insights into the role of vitamin D and muscle function
have arisen from the study of certain pathological settings such as
chronic inflammatory conditions. These conditions share pheno-
typic characteristics to vitamin D deficiency states and VDR-null
mice. Myopathy is a feature of a number of chronic inflammatory
syndromes. Chronic inflammation has been linked to pathophys-
iological mechanisms which implicate non-genomic and genomic
1,25-(OH)2D3-mediated signaling pathways. Skeletal muscle may
be considered as having a level of plasticity, allowing it to
respond to environmental, physiological and pathophysiological
stimuli that elicit alterations in size, fiber-type and metabolism.
Molecular factors such as insulin-like growth factors, calcineurin,
desmin, Myf5, Mrf4, MyoD and myogenin have been identified
as positive regulators of muscle size, while tumor necrosis factor
(TNF)-α, myostatin and components of the ubiquitin pathway,
have been recognized as regulators of muscle wasting. Emerging
evidence supports a role for VDR in the contractile and metabolic
function of both skeletal and cardiac muscle in health and dis-
ease (Figure 1). The expression of VDR and its interaction at
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FIGURE 1 | VDR as a marker of cardiac dysfunction induced by cancer
cachexia. Vitamin D Receptor (VDR) as a molecular marker of maladaptive
responses due to cancer cachexia in the heart. VDR has been linked to
having cardioprotective mechanisms by maintaining contractile kinetics,
and regulating fibrosis and hypertrophy (Yuan et al., 2007; Tishkoff et al.,
2008; Koleganova et al., 2009).
the molecular level with proteins that are involved in inflamma-
tion, signaling and ultimately contractile function of both skeletal
and cardiac muscle is of importance. In vitro cell culture mod-
els, in vivo rodent models as well as clinical studies in humans are
starting to clarify the mechanisms of vitamin D action mediated
via the VDR in muscle in order to enhance our understanding
of their role in inflammatory mediated myopathy and muscle
weakness (Girgis et al., 2012, 2013, 2014).
Exercise-induced muscle damage has been shown to increase
the expression of VDR while altering gene expression of inflam-
matory cytokines such as interleukin (IL)-6 and TNF-α and
alterations in signaling molecules involved with vitamin D signal-
ing pathways such as phosphorylation of AMPK, p38, ERK1/2,
IKK, and IκB simultaneously (Choi et al., 2013). An inverse rela-
tionship is generally reported for vitamin D, cancer and muscle
structure and function. Alterations in metabolic status and physi-
cal activity play a role, however paraneoplastic syndromes such as
cancer cachexia integrate many metabolic and catabolic molecu-
lar mechanisms which result in pathophysiological skeletal and
more recently cardiac muscle effects (Choi et al., 2013). Low
serum vitamin D levels are highly prevalent in advanced can-
cer patients with cachexia or fatigue (Dev et al., 2011). Elevated
levels of inflammatory circulating factors, include C-reactive pro-
tein (CRP), a currently utilized clinical marker. The VDR axis
is reported to play a fundamental role with possible association
between CRP and VDR gene polymorphisms, in cancer patients
with cachexia. This suggests the notion of cachexia-prone geno-
types or to cachexia-resistant genotypes (Punzi et al., 2012). It has
been suggested that tumor associated effects such as these may in
part be addressed by nutraceutical vitamin D supplemented diets
to improve vitamin D status (Endo et al., 1998; Morley, 2009;
Morley et al., 2009; Strohle et al., 2010).
Data arising from the study of muscle structure and func-
tion in cancer cachexia has revealed new insights into vitamin
D. Cancer cachexia is a debilitating clinical syndrome which
causes up to 30% of cancer related deaths by either immobility,
respiratory and/or cardiac failure (Fearon, 2008) and is charac-
terized by weight loss; up-regulation of inflammatory markers
such as IL-6, IL-1, TNF-α and interferon gamma (IFN)γ; hyper-
calcemia; and insulin resistance (Argiles et al., 2003; Sato et al.,
2003; Jackman and Kandarian, 2004; Evans et al., 2008; Tisdale,
2009; Asp et al., 2010). The interaction between host factors and
tumor cells is proposed to cause an excess production of cytokines
and improper stimulation of downstream signaling molecules
which results in weakness and decreased physical activity; thus
highlighting the detrimental effects of cachexia on quality of life
(Dahele et al., 2007). Of these cytokines, IL-6 is thought to be a
key mediator of skeletal and cardiac muscle wasting in the patho-
genesis of CC (Argiles et al., 2003; Haddad et al., 2005; Baltgalvis
et al., 2008; Tisdale, 2009; Carson and Baltgalvis, 2010). Current
treatment strategies are limited and do little to improve survival
(Michael and Tannock, 1998; Mantovani et al., 2008).
More recently, we have identified a link between IL-6, the myo-
genic transcriptional regulator MEF2C and muscle breakdown
due to CC (Shum et al., 2012). Different underlying molecu-
lar effects may also underlie the pathological changes in skeletal
vs. cardiac muscle due to cancer (Shum et al., 2012; Tan et al.,
2013; Shum et al., 2013; Falconer et al., in press) “Exercise genes”
have now been identified in humans, which now opens the gate-
way for analyses that focus on the genetic basis of performance.
These include the genes encoding for: the angiotensin converting
enzyme, alpha-actinin 3, bradykinin, ciliary neurotrophic factor,
interleukin-15, insulin-like growth factor II, myostatin and the
VDR which have been proposed to play a role in inter-subject
variability in muscle strength or size. Current data is only avail-
able from healthy subjects, hence genetic variability that may
account for these effects still requires further analysis particularly
in the context of muscle disease (Stewart and Rittweger, 2006).
Furthermore, conversion toward a fatigue prone, type II skele-
tal myofiber phenotype has been observed due to cancer, which
potentially makes this condition treatable with vitamin D.
Cardiac muscle effects due to cancer cachexia. Cardiac weight
loss is a relatively unreported feature in cancer cachexia although
autopsy studies revealed that “cardiac atrophy” is a prominent
feature in advanced cancer patients (Hellerstein and Santiago-
Stevenson, 1950). Recent studies have demonstrated that the
reversal of cardiac and skeletal muscle weight loss increased
longevity in mouse models of cancer cachexia, implying that
these effects on the heart may contribute to poor prognosis in
cancer patients (Zhou et al., 2010). The molecular basis of this
cardiomyopathy induced by cancer cachexia is unclear. We and
others have established the IL-6 driven, colon 26 (C26) carci-
noma cachexia mouse model to study cancer cachexia (Tanaka
et al., 1990; Asp et al., 2010; Zhou et al., 2010; Shum et al.,
2012). The C26model demonstrates significant body wasting, has
no metastases to the heart, thus effects seen are largely due to
the tumor or the host-tumor response (Matsumoto et al., 1999;
Schwarzkopf et al., 2006; Strassmann et al., 1992). Features of
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cardiac wasting in the end stages of cachexia (i.e., 20–25% body
weight loss) observed in C26 and other cachectic animal models
include: heart weight loss; marked fibrosis; oxidative modifi-
cations; reduced expression of contractile apparatus proteins;
no increase of apoptosis; and lower ejection fraction (Fukuda
et al., 2009; Springer et al., 2009; Marin-Corral et al., 2010;
Tian et al., 2010; Shum et al., Unplublished Data). Genes that
mediate muscle atrophy such as atrogin-1 andMurf-1, were unal-
tered in the heart unlike skeletal muscle; implying that cardiac
wasting occurs via different molecular pathways (Zhou et al.,
2010; Shum et al., 2013; Unplublished Data). Vitamin D and
its gene effects in the context of functional consequences have
been described in skeletal muscle cell culture models, cardiac
muscle and smooth muscle (Meems et al., 2011; Girgis et al.,
2014). However, the roles of VDR and 1,25-(OH)2D3 need fur-
ther characterization in the context of muscle wasting due to
cancer cachexia (Figure 1).
VitaminD and cardiac pathology.Vitamin D and its analogs may
potentially have palliative effects in the cardiovascular system.
Long term exposure to angiotensin II has been shown to induce
hypertension, cardiac hypertrophy, activation of the hypertrophic
fetal gene program atrial natriuretic peptide (ANP), B-type natri-
uretic peptide and alpha skeletal actin gene expression), increased
expression of the pro-hypertrophic modulatory calcineurin
inhibitor protein 1 (MCIP 1), and increased fibrosis with aug-
mented procollagen 1 and 3 gene expression. Co-administration
of paricalcitol (a vitamin D analog with agonist properties) in an
animal model of non-renin-dependent cardiac hypertrophy par-
tially reversed the reported AII-dependent effects. Interestingly,
the effects of agonist-bound vitamin D receptor appeared to elicit
potent anti-hypertrophic activity in this model of cardiac hyper-
trophy. The anti-hypertrophic activity appears to be at least par-
tially intrinsic to the cardiac myocyte and may involve suppres-
sion of the MCIP 1 protein (Chen and Gardner, 2013). Though
the cardiovascular system is not thought to represent a classical
target for 1,25-(OH)2D3 and retinoic acid (RA), it is clear that
both cardiomyocytes and vascular smoothmuscle cells respond to
these nuclear receptor hormones (NRHs) with changes in growth
characteristics and gene expression (Figure 1). These NRHs sup-
press many of the phenotypic correlates of endothelin-induced
hypertrophy in a cultured neonatal rat cardiac ventriculocyte
model. Each of these NRHs reduced endothelin-stimulated ANP
secretion in a dose-dependent manner and when the two were
used in combination, they proved to be more effective than when
either NRHwas used alone. 1,25-(OH)2D3 abrogated the increase
in cell size seen after endothelin treatment. These findings sug-
gest that liganded vitamin D and retinoid receptors are capable of
modulating the hypertrophic process in vitro and that agents act-
ing through these or similar signaling pathways may be of value in
probing the molecular mechanisms underlying hypertrophy (Wu
et al., 1996) (Figure 1).
Transcriptome-wide effects and muscle
Recently, transcriptome-wide approaches have been applied to
muscle in order to get a global view of changes that occur
due to various stimuli, for example structural vs. metabolic.
The transcriptional profile of VDR mRNA isoforms has been
examined for differences in bone, cartilage and paravertebral
muscles between tissues from curve concavity and convexity.
VDR was differentially expressed in paravertebral muscles in
patients with juvenile idiopathic scoliosis (JIS) and adult idio-
pathic scoliosis (AIS). The VDRl isoform appears to contribute
to curve concavity in paravertebral muscles. Furthermore, mus-
cular transcriptome differentiation was evident between curve
concavity and convexity in JIS patients. Tob2 and MED13 gene
expression in paravertebral muscles appear to differentiate the
two types of idiopathic scoliosis (Nowak et al., 2012).
Gene expression has been examined in skeletal muscle tissue
of obese insulin-resistant subjects before and after a euglycemic-
hyperinsulinemic clamp to determine the pathogenesis of insulin
resistance. Differential gene expression was demonstrated for
enzymes, transcription, and translation regulators, transporters,
G protein-coupled receptors, cytokines, and ligand-dependent
nuclear receptors. Metabolic pathways that incorporated, inflam-
matory signaling and nuclear receptors were also significantly
different. These included LXR/RXR activation, VDR/RXR acti-
vation, interleukin IL-8, acute phase response, IL-10, triggering
receptor expressed on myeloid cells 1, peroxisome proliferator-
activated receptor, G-beta/gamma and hepatocyte growth factor
and IL6 signaling (Rudkowska et al., 2013).
Comparisons between transcriptomes and proteomes in mus-
cle tissues and activated CD4+ and CD8+ T lymphocytes
(T-cells) analyzed using Affymetrix microarrays and mass spec-
trometry, from type 2 diabetes (T2DM) subjects and matched
non-diabetic controls, demonstrated reduced gene expression
for insulin receptor (INSR), VDR, insulin degrading enzyme,
Akt, insulin receptor substrate-1 (IRS-1), IRS-2, glucose trans-
porter 4 (GLUT4), and enzymes of the glycolytic pathway in the
T2DM subjects compared controls. Increased gene expression was
shown for plasma cell glycoprotein-1, TNFα, and gluconeogenic
enzymes in T2DM subjects. Observed alterations in transcrip-
tomes and proteomes between muscle and activated T-cells of
T2DMwere comparable suggesting a more global molecular basis
for insulin resistance (Stentz and Kitabchi, 2007).
Conclusion and perspectives
There is now clear evidence supporting a significant role for
vitamin D in the biology and function of skeletal and cardiac
muscle. Current evidence outlines a number of effects of vita-
min D on these muscle types including intracellular calcium
handling, differentiation and contractile protein composition.
However further study using novel investigative strategies is still
warranted to better delineate the role and functions of vita-
min D in muscle. The molecular interplay between cytokine
signaling, VDR expression, genetic variability in patients with
myopathy due to chronic inflammatory conditions such as can-
cer cachexia may reveal the molecular basis for changes that
have been observed in skeletal and cardiac muscle. Early tran-
scriptomic studies on the effects of cytokines in muscle wasting
due to cancer cachexia have provided clues regarding potential
molecular mechanisms induced by cytokines that drive muscle
wasting which may potentially also implicate vitamin D medi-
ated transcriptional mechanisms although this still remains to
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be defined. A better characterization of the role of VDR in the
context of inflammation-mediated muscle wasting and weakness
may also potentially translate into significant clinical applica-
tions by informing nutraceutical approaches using vitamin D
supplementation as a potential strategy for reversing muscle
wasting.
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